MAFRA: Biological MArkers of FRAilty in Elderly Subjects

Sponsor
CHU de Reims (Other)
Overall Status
Completed
CT.gov ID
NCT02816580
Collaborator
(none)
254
1
1
55.3
4.6

Study Details

Study Description

Brief Summary

Epidemiological data from Europe have shown that around 30% of subjects aged over 65 years of age are pre-frail, and 15% are frail. Recent research has demonstrated that identifying frailty and implementing preventive measures can help to slow cognitive decline. Screening and treating frailty seem to be a good start towards preventing dependency.

On the premise that this frailty is the result of more pronounced tissue alterations in certain elderly subjects, assessment of post-translational modification derived products (PTMDP) represents an innovative evaluation method. These include advanced glycation end-products (AGE), and carbamylation-derived products (homocitrulline). Indeed, the intensity of these modifications increases with ageing, and assessing the products resulting from these alterations could show the existence of differences according to frailty status. This would make it possible to adapt treatment accordingly in elderly subjects.

Condition or Disease Intervention/Treatment Phase
  • Other: Blood collection
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
254 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
PTMDP (Post-translational Modification Derived Products) as Markers of Frailty in Elderly Subjects
Actual Study Start Date :
Feb 23, 2015
Actual Primary Completion Date :
Oct 2, 2019
Actual Study Completion Date :
Oct 2, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: elderly subjects

Other: Blood collection

Outcome Measures

Primary Outcome Measures

  1. post-translational modification derived-products (PTMDP) quantification by Multidimensional Chromatography Coupled withTandem Mass Spectrometry (LC/LC-MS/MS) [baseline]

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • With social security coverage

  • Accept to participate in the study and sign informed consent for the study and for the collection of biological samples

Exclusion Criteria:
  • < 65 yo

Contacts and Locations

Locations

Site City State Country Postal Code
1 Chu de Reims Reims France 51092

Sponsors and Collaborators

  • CHU de Reims

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
CHU de Reims
ClinicalTrials.gov Identifier:
NCT02816580
Other Study ID Numbers:
  • PO14057
First Posted:
Jun 28, 2016
Last Update Posted:
Mar 4, 2022
Last Verified:
Feb 1, 2022
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 4, 2022